CeriBell (NASDAQ:CBLL) CTO Sells $206,238.72 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 11,112 shares of CeriBell stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $18.56, for a total transaction of $206,238.72. Following the transaction, the chief technology officer directly owned 166,912 shares of the company’s stock, valued at approximately $3,097,886.72. This trade represents a 6.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raymond Woo also recently made the following trade(s):

• On Monday, March 2nd, Raymond Woo sold 8,087 shares of CeriBell stock. The stock was sold at an average price of $18.25, for a total transaction of $147,587.75.
• On Monday, February 23rd, Raymond Woo sold 705 shares of CeriBell stock. The shares were sold at an average price of $19.79, for a total transaction of $13,951.95.

CeriBell Price Performance

CBLL stock opened at $18.57 on Monday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.35 and a current ratio of 9.73. The firm has a 50 day moving average price of $19.31 and a 200-day moving average price of $17.49. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $24.33. The firm has a market capitalization of $698.97 million, a price-to-earnings ratio of -12.63 and a beta of 0.94.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07. The company had revenue of $24.78 million for the quarter, compared to the consensus estimate of $23.95 million. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%. Equities research analysts forecast that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CBLL. BTIG Research reiterated a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research note on Wednesday, January 28th. TD Cowen restated a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Finally, Canaccord Genuity Group upped their target price on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, CeriBell currently has an average rating of “Moderate Buy” and a consensus price target of $23.20.

Institutional Investors Weigh In On CeriBell

A number of hedge funds have recently added to or reduced their stakes in CBLL. Bank of New York Mellon Corp boosted its stake in shares of CeriBell by 1,945.9% in the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after buying an additional 1,162,200 shares during the last quarter. KCM Capital Inc purchased a new stake in CeriBell during the fourth quarter valued at $21,930,000. Royce & Associates LP bought a new position in CeriBell in the fourth quarter valued at about $11,695,000. Adage Capital Partners GP L.L.C. purchased a new position in CeriBell in the fourth quarter worth about $10,965,000. Finally, CenterBook Partners LP grew its stake in shares of CeriBell by 448.0% during the 3rd quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock valued at $5,476,000 after purchasing an additional 389,584 shares during the period.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.